Arcus Biosciences Inc (NYSE: RCUS)’s stock price has decreased by -0.64 compared to its previous closing price of 14.12. However, the company has seen a -1.20% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-14 that Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will report important updates in 2025. One of Domvanalimab’s combinations showed that it can help overall survival by a whopping 36% in NSCLC. It also had lower discontinuation rates than chemotherapy.
Is It Worth Investing in Arcus Biosciences Inc (NYSE: RCUS) Right Now?
RCUS has 36-month beta value of 0.85. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for RCUS is 49.27M, and currently, short sellers hold a 15.73% ratio of that float. The average trading volume of RCUS on January 20, 2025 was 738.49K shares.
RCUS’s Market Performance
RCUS stock saw a decrease of -1.20% in the past week, with a monthly decline of -15.02% and a quarterly a decrease of -21.44%. The volatility ratio for the week is 3.90%, and the volatility levels for the last 30 days are 4.43% for Arcus Biosciences Inc (RCUS). The simple moving average for the last 20 days is -5.99% for RCUS stock, with a simple moving average of -12.16% for the last 200 days.
Analysts’ Opinion of RCUS
Many brokerage firms have already submitted their reports for RCUS stocks, with H.C. Wainwright repeating the rating for RCUS by listing it as a “Neutral.” The predicted price for RCUS in the upcoming period, according to H.C. Wainwright is $20 based on the research report published on October 21, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see RCUS reach a price target of $29. The rating they have provided for RCUS stocks is “Overweight” according to the report published on October 08th, 2024.
BofA Securities gave a rating of “Neutral” to RCUS, setting the target price at $33 in the report published on November 18th of the previous year.
RCUS Trading at -10.40% from the 50-Day Moving Average
After a stumble in the market that brought RCUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.92% of loss for the given period.
Volatility was left at 4.43%, however, over the last 30 days, the volatility rate increased by 3.90%, as shares sank -12.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.83% lower at present.
During the last 5 trading sessions, RCUS fell by -1.20%, which changed the moving average for the period of 200-days by -20.82% in comparison to the 20-day moving average, which settled at $14.92. In addition, Arcus Biosciences Inc saw -5.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCUS starting from Goeltz II Robert C., who sale 3,594 shares at the price of $15.00 back on Dec 31 ’24. After this action, Goeltz II Robert C. now owns 60,138 shares of Arcus Biosciences Inc, valued at $53,910 using the latest closing price.
Goeltz II Robert C., the Officer of Arcus Biosciences Inc, proposed sale 3,594 shares at $15.00 during a trade that took place back on Dec 31 ’24, which means that Goeltz II Robert C. is holding shares at $53,910 based on the most recent closing price.
Stock Fundamentals for RCUS
Current profitability levels for the company are sitting at:
- -1.21 for the present operating margin
- 0.96 for the gross margin
The net margin for Arcus Biosciences Inc stands at -1.03. The total capital return value is set at -0.31. Equity return is now at value -49.77, with -22.10 for asset returns.
Based on Arcus Biosciences Inc (RCUS), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -2.72. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -159.0.
Currently, EBITDA for the company is -283.0 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 4.34. The receivables turnover for the company is 12.52for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.23.
Conclusion
To put it simply, Arcus Biosciences Inc (RCUS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
